Education
About Us
Working with TipRanks
Follow Us
Verve Therapeutics (VERV)
NASDAQ:VERV
Top Page
Verve Therapeutics
(NASDAQ:VERV)38Underperform
Positive Factors
Financial Stability
VERV ended with a strong cash position, providing financial stability into mid-2027.
Strategic Partnerships
Lilly obtained opt-in rights to VERVE-102, allowing for a 50/50 cost/profit sharing of its commercialization in the US market, in exchange for funding 33% of worldwide development expenses.
Negative Factors
Collaborations and Partnerships
Decision by VRTX to discontinue its collaboration with VERV in light of changing priorities.
Verve Therapeutics (VERV) vs. S&P 500 (SPY)
Market Cap
$543.43M
Dividend YieldN/A
Average Volume (3M)1.61M
Price to Earnings (P/E)―
Beta (1Y)3.41
Revenue Growth174.98%
EPS Growth25.06%
CountryUS
Employees255
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.35
Shares Outstanding88,795,770
10 Day Avg. Volume1,407,642
30 Day Avg. Volume1,611,826
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)22.46
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$21.43Price Target Upside250.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Verve Therapeutics Business Overview & Revenue Model
Company DescriptionVerve Therapeutics (VERV) is a biotechnology company focused on developing transformative therapies for patients with cardiovascular diseases. The company operates within the life sciences sector, specializing in gene editing technologies. Verve's core products are designed to provide effective, long-term treatment options for cardiovascular conditions by addressing the underlying genetic causes of these diseases.
How the Company Makes MoneyVerve Therapeutics makes money primarily through the development and commercialization of its innovative gene editing therapies. The company's revenue streams include potential milestone payments and royalties from partnerships with larger pharmaceutical companies, licensing agreements for its proprietary technologies, and future sales of its therapeutic products once they receive regulatory approval. Verve may also engage in strategic collaborations to advance its research and development efforts, which can provide additional funding and resources to support its operational and clinical endeavors.
Verve Therapeutics Financial Statement Overview
Summary
Verve Therapeutics exhibits strong revenue growth, but faces challenges with profitability, as indicated by its negative net profit margin and high operational costs. The balance sheet is stable with low leverage, yet negative cash flows pose a risk.Income Statement
Verve Therapeutics showed positive revenue growth with TTM revenue at $24.4M, a significant increase from $11.8M in the previous year. However, the company has negative net income, leading to a concerning net profit margin of -807.5% for the TTM. The EBIT margin is also negative at -928.6%, indicating high operational costs relative to revenue.40
Negative
Balance Sheet
The debt-to-equity ratio stands at 0.14, suggesting manageable leverage. However, return on equity is negative due to consistent losses. The equity ratio is at 76.6%, indicating a strong equity position relative to total assets. Overall, the balance sheet shows stability in terms of leverage but struggles with profitability.55
Neutral
Cash Flow
The free cash flow is negative, with a slight increase in operating cash outflows. The operating cash flow to net income ratio is 0.80, indicating that cash flow is not adequately covering the losses. The company relies heavily on financing activities to maintain liquidity.45
Neutral
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 24.40M | 11.76M | 1.94M | 0.00 | 0.00 | 0.00 | Gross Profit |
| 17.83M | 6.30M | -4.77M | -3.38M | -1.33M | -106.00K | EBIT |
| -226.54M | -223.12M | -165.69M | -87.07M | -40.63M | -13.64M | EBITDA |
| -219.97M | -217.67M | -162.88M | -85.53M | -39.30M | -13.54M | Net Income Common Stockholders |
| -197.03M | -200.07M | -157.39M | -118.64M | -45.54M | -19.02M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 623.95M | 623.95M | 554.81M | 360.44M | 72.11M | 18.78M | Total Assets |
| 752.69M | 752.69M | 679.22M | 384.12M | 78.41M | 21.65M | Total Debt |
| 74.91M | 74.91M | 81.92M | 1.96M | 125.16M | 35.05M | Net Debt |
| -131.27M | -131.27M | -33.49M | -62.38M | 116.17M | 32.06M | Total Liabilities |
| 153.19M | 153.19M | 128.29M | 26.77M | 142.32M | 41.20M | Stockholders Equity |
| 599.50M | 599.50M | 550.93M | 357.35M | -63.91M | -19.55M |
| Cash Flow | Free Cash Flow | ||||
| -162.06M | -158.83M | -135.56M | -82.24M | -38.69M | -9.30M | Operating Cash Flow |
| -157.53M | -149.55M | -122.33M | -77.88M | -35.27M | -7.44M | Investing Cash Flow |
| 36.44M | 27.69M | -155.96M | -239.10M | -51.13M | -12.76M | Financing Cash Flow |
| 201.43M | 212.58M | 328.96M | 377.09M | 92.63M | 17.95M |
Verve Therapeutics Technical Analysis
Negative
6.12
Price Trends
6.83
Negative
6.27
Negative
5.95
Positive
Market Momentum
-0.26
Positive
37.17
Neutral
11.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERV, the sentiment is Negative. The current price of 6.12 is below the 20-day moving average (MA) of 7.48, below the 50-day MA of 6.83, and above the 200-day MA of 5.95, indicating a neutral trend. The MACD of -0.26 indicates Positive momentum. The RSI at 37.17 is Neutral, neither overbought nor oversold. The STOCH value of 11.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VERV.
Verve Therapeutics Risk Analysis
Verve Therapeutics disclosed 87 risk factors in its most recent earnings report. Verve Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Verve Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
50 Neutral | $146.11M | ― | -119.89% | ― | 150.95% | 5.48% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
49 Neutral | $3.73B | ― | -18.96% | ― | -89.95% | -123.71% | |
45 Neutral | $2.21B | ― | -51.36% | ― | -83.18% | -144.95% | |
42 Neutral | $179.37M | ― | -344.56% | ― | -74.04% | 48.16% | |
39 Underperform | $941.49M | ― | -59.52% | ― | 59.55% | 3.09% | |
38 Underperform | $543.43M | ― | -40.27% | ― | 174.98% | 25.06% |
* Healthcare Sector Average
Performance Comparison
VERV
Verve Therapeutics
6.12
-8.95
-59.39%
SGMO
Sangamo Biosciences
0.86
-0.15
-14.85%
EDIT
Editas Medicine
1.76
-7.32
-80.62%
NTLA
Intellia Therapeutics
9.10
-20.85
-69.62%
CRSP
Crispr Therapeutics AG
43.45
-37.38
-46.25%
BEAM
Beam Therapeutics
26.44
-11.84
-30.93%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.